On ECHEMI
Home > Drugs > Harbin Pharmaceutical Group Bioengineering Co., Ltd.
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
  • Founded in:

    1995-02-20
  • Country:

    China China
  • Address:

    No. 99, Zhuhai Road, Limin Development Zone, Hulan District, Harbin
  • Tax NO.:

    91230111128024298B
  • Registered Funds:

    186.0655 million yuan
  • Website:

  • Email:

Related Drugs
Recombinant human interferon α2b for injection
Recombinant human interferon α2b, human serum albumin.
Name Description Content CAS NO. Registered Holders
Recombinant Human Interferon α2b

No specific description provided

More

No specific description provided

0
Human serum albumin

No specific description provided

More

No specific description provided

70024-90-7 2
Chuanhuning for injection
Main ingredients: Chuanhunning
Name Description Content CAS NO. Registered Holders
14-deoxy-11,12-didehydroandrographolide 3,19-disuccinate

76958-99-1 8
Recombinant human interferon α2b for injection (Pseudomonas)
Recombinant human interferon alpha;1b.
Name Description Content CAS NO. Registered Holders
Recombinant human interferon alpha;1b

The average serum concentration of Anfulong is the same after intramuscular injection and subcutaneous injection, with the highest serum concentration of about 1.2-33.6 units/ml, occurring 1 to 24 hours later; the elimination half-life is 4-12 hours, and the maximum blood concentration occurs 3.5-8 hours after medication. It can make hepatitis B e antigen negative, normalize transaminase levels, reduce liver inflammation, and delay the progression to cirrhosis and improve the quality of life in 20%-30% of patients. It can normalize serum ALT, improve liver tissue and reduce the amount of virus in patients with chronic hepatitis C. It has clinical significance in tumor regression or stabilization of hairy cell leukemia, and in the treatment of patients with Kaposi's sarcoma related to AIDS. It is of great significance for patients with chronic myeloid leukemia, and can also be used as an adjunct to intermittent treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

More

The average serum concentration of Anfulong is the same after intramuscular injection and subcutaneous injection, with the highest serum concentration of about 1.2-33.6 units/ml, occurring 1 to 24 hours later; the elimination half-life is 4-12 hours, and the maximum blood concentration occurs 3.5-8 hours after medication. It can make hepatitis B e antigen negative, normalize transaminase levels, reduce liver inflammation, and delay the progression to cirrhosis and improve the quality of life in 20%-30% of patients. It can normalize serum ALT, improve liver tissue and reduce the amount of virus in patients with chronic hepatitis C. It has clinical significance in tumor regression or stabilization of hairy cell leukemia, and in the treatment of patients with Kaposi's sarcoma related to AIDS. It is of great significance for patients with chronic myeloid leukemia, and can also be used as an adjunct to intermittent treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

0
Alprostadil Injection
The main ingredient is prostaglandin E1, and its chemical name is: (1R, 2R, 3R)-3-hydroxy 2-[(E)-(3S)-3-hydroxy-1-octenyl]-5-oxocyclopentaneheptanoic acid. Molecular formula: C20H34O5. Molecular weight: 354.49. Excipients: soybean oil (for injection), soybean lecithin (for injection), glycerol (for injection), citric acid, and water for injection.
Name Description Content CAS NO. Registered Holders
Prostaglandin E1

Dilate blood vessels, inhibit platelet aggregation; stabilize liver cell membranes and improve liver function

More

Dilate blood vessels, inhibit platelet aggregation; stabilize liver cell membranes and improve liver function

745-65-3 14
Alprostadil Injection
Prostaglandin E1. Excipients: refined soybean oil, refined lecithin, concentrated glycerol, oleic acid, sodium hydroxide, water for injection.
Name Description Content CAS NO. Registered Holders
Prostaglandin E1

Dilate blood vessels, inhibit platelet aggregation; stabilize liver cell membranes and improve liver function

More

Dilate blood vessels, inhibit platelet aggregation; stabilize liver cell membranes and improve liver function

745-65-3 14
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.